Search
Now showing items 21-30 of 39
Precision treatment in ACS – role of assessing fibrinolysis
(2021-03-01)
Despite advancements in pharmacotherapy and interventional strategies, patients with acute coronary syndrome (ACS) remain at risk of recurrent thrombotic events. In addition to an enhanced tendency to thrombus formation, ...
Role, laboratory assessment and clinical relevance of fibrin, factor XIII and endogenous fibrinolysis in arterial and venous thrombosis
(2021-02-02)
Diseases such as myocardial infarction, ischaemic stroke, peripheral vascular disease and venous thromboembolism are major contributors to morbidity and mortality. Procoagulant, anticoagu-lant and fibrinolytic pathways are ...
Prevalence of Thrombotic Complications in ICU-Treated Patients With Coronavirus Disease 2019 Detected With Systematic CT Scanning
(2021-01-06)
Objective: Severe Coronavirus disease 2019 (COVID-19) is associated with an extensive pneumonitis, and frequent coagulopathy. We sought the true incidence of thrombotic complications in critically ill patients with severe ...
Endogenous fibrinolysis - relevance to clinical thrombosis risk assessment
(2020-12-09)
The development of an obstructive luminal thrombus is pathological and considered a failure of endogenous fibrinolysis. The consequences may be fatal, or result in lasting downstream organ damage. Therefore, assessment of ...
2-oxothiazolidine-4-carboxylic acid inhibits vascular calcification via induction of glutathione synthesis
(2020-09-12)
Arterial medial calcification (AMC), the deposition of hydroxyapatite in the medial layer of the arteries, is a known risk factor for cardiovascular events. Oxidative stress is a known inducer of AMC and endogenous ...
Bioprosthetic valve thrombosis and degeneration following transcatheter aortic valve implantation (TAVI)
(2020-09-09)
Bioprosthetic valve thrombosis (BPVT) is a recognised complication of prosthetic aortic valves and can be seen in up to 13% of patients after transcatheter implantation.The mechanism of BPVT is not well known, abnormal ...
Reduction in ACE2 may mediate the prothrombotic phenotype in COVID-19
(2020-07-20)
This commentary refers to ‘Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy’, by R.M. Inciardi et al., doi: 10.1093/eurheartj/ehaa583.
Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome
(2020-07-01)
Abstract: Acute coronary syndrome and atrial fibrillation are both common, and can occur in the same patient. Combination therapy with dual antiplatelet therapy and oral anticoagulation increases risk of bleeding. Where ...